Cargando…
The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials
An increase in the number of identified therapeutic cancer targets achieved through recent biomedical research has resulted in the generation of a large number of molecules that need to be tested further. Current development of (anticancer) drugs is a rather inefficient process that for an average n...
Autores principales: | Marchetti, S, Schellens, J H M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360360/ https://www.ncbi.nlm.nih.gov/pubmed/17726450 http://dx.doi.org/10.1038/sj.bjc.6603925 |
Ejemplares similares
-
Psychopharmacology at the era of EMEA (European Medicines Agency)
por: Pestana, Luis Camara, et al.
Publicado: (2010) -
EMEA and Gene Therapy Medicinal Products Development in the European Union
por: Papaluca Amati, Marisa, et al.
Publicado: (2003) -
Anne Richards, Chief Investment Officer, Head of EMEA - CERN & Society Board Meeting
por: Brice, Maximilien
Publicado: (2014) -
EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations
por: Boesen, Kim, et al.
Publicado: (2021) -
FDA relations during drug development
por: Mitchel, Jules T.
Publicado: (2000)